RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Karunya Kandimalla to Alzheimer Disease

This is a "connection" page, showing publications Karunya Kandimalla has written about Alzheimer Disease.
Connection Strength

5.186
  1. Nelson D, Thompson KJ, Wang L, Wang Z, Eberts P, Azarin SM, Kalari KR, Kandimalla KK. Pericyte Control of Gene Expression in the Blood-Brain Barrier Endothelium: Implications for Alzheimer's Disease. J Alzheimers Dis. 2024; 99(s2):S281-S297.
    View in: PubMed
    Score: 0.556
  2. Wang Z, Sharda N, Omtri RS, Li L, Kandimalla KK. Amyloid-Beta Peptides 40 and 42 Employ Distinct Molecular Pathways for Cell Entry and Intracellular Transit at the Blood-Brain Barrier Endothelium. Mol Pharmacol. 2023 Nov; 104(5):203-213.
    View in: PubMed
    Score: 0.541
  3. Zhou AL, Sharda N, Sarma VV, Ahlschwede KM, Curran GL, Tang X, Poduslo JF, Kalari KR, Lowe VJ, Kandimalla KK. Age-Dependent Changes in the Plasma and Brain Pharmacokinetics of Amyloid-? Peptides and Insulin. J Alzheimers Dis. 2022; 85(3):1031-1044.
    View in: PubMed
    Score: 0.484
  4. Wang Z, Sharda N, Curran GL, Li L, Lowe VJ, Kandimalla KK. Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium. Mol Pharm. 2021 11 01; 18(11):4148-4161.
    View in: PubMed
    Score: 0.477
  5. Ahlschwede KM, Curran GL, Rosenberg JT, Grant SC, Sarkar G, Jenkins RB, Ramakrishnan S, Poduslo JF, Kandimalla KK. Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. Nanomedicine. 2019 02; 16:258-266.
    View in: PubMed
    Score: 0.387
  6. Omtri RS, Thompson KJ, Tang X, Gali CC, Panzenboeck U, Davidson MW, Kalari KR, Kandimalla KK. Differential Effects of Alzheimer's Disease A?40 and 42 on Endocytosis and Intraneuronal Trafficking. Neuroscience. 2018 03 01; 373:159-168.
    View in: PubMed
    Score: 0.368
  7. Jaruszewski KM, Curran GL, Swaminathan SK, Rosenberg JT, Grant SC, Ramakrishnan S, Lowe VJ, Poduslo JF, Kandimalla KK. Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. Biomaterials. 2014 Feb; 35(6):1967-76.
    View in: PubMed
    Score: 0.277
  8. Agyare EK, Leonard SR, Curran GL, Yu CC, Lowe VJ, Paravastu AK, Poduslo JF, Kandimalla KK. Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-? proteins in the cerebral vasculature. Mol Pharm. 2013 May 06; 10(5):1557-65.
    View in: PubMed
    Score: 0.263
  9. Omtri RS, Davidson MW, Arumugam B, Poduslo JF, Kandimalla KK. Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: ramifications for the Alzheimer's drug discovery. Mol Pharm. 2012 Jul 02; 9(7):1887-97.
    View in: PubMed
    Score: 0.249
  10. Poduslo JF, Gilles EJ, Ramakrishnan M, Howell KG, Wengenack TM, Curran GL, Kandimalla KK. HH domain of Alzheimer's disease Abeta provides structural basis for neuronal binding in PC12 and mouse cortical/hippocampal neurons. PLoS One. 2010 Jan 21; 5(1):e8813.
    View in: PubMed
    Score: 0.212
  11. Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF. Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. PLoS One. 2009; 4(2):e4627.
    View in: PubMed
    Score: 0.199
  12. Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, Kandimalla KK. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm Res. 2008 Nov; 25(11):2674-84.
    View in: PubMed
    Score: 0.192
  13. Kandimalla KK, Wengenack TM, Curran GL, Gilles EJ, Poduslo JF. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice. J Pharmacol Exp Ther. 2007 Aug; 322(2):541-9.
    View in: PubMed
    Score: 0.176
  14. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Ramirez-Alvarado M, Poduslo JF. Physiological and biophysical factors that influence Alzheimer's disease amyloid plaque targeting of native and putrescine modified human amyloid beta40. J Pharmacol Exp Ther. 2006 Jul; 318(1):17-25.
    View in: PubMed
    Score: 0.162
  15. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther. 2005 Jun; 313(3):1370-8.
    View in: PubMed
    Score: 0.151
  16. Zhou AL, Swaminathan SK, Salian VS, Wang L, Curran GL, Min HK, Lowe VJ, Kandimalla KK. Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood-Brain Barrier. Mol Pharm. 2024 May 06; 21(5):2176-2186.
    View in: PubMed
    Score: 0.142
  17. Swaminathan SK, Ahlschwede KM, Sarma V, Curran GL, Omtri RS, Decklever T, Lowe VJ, Poduslo JF, Kandimalla KK. Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain. J Cereb Blood Flow Metab. 2018 05; 38(5):904-918.
    View in: PubMed
    Score: 0.088
  18. Poduslo JF, Howell KG, Olson NC, Ramirez-Alvarado M, Kandimalla KK. Alzheimer's disease amyloid ?-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils. Biochemistry. 2012 May 15; 51(19):3993-4003.
    View in: PubMed
    Score: 0.062
  19. Jaruszewski KM, Ramakrishnan S, Poduslo JF, Kandimalla KK. Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine. 2012 Feb; 8(2):250-60.
    View in: PubMed
    Score: 0.058
  20. Ramakrishnan M, Kandimalla KK, Wengenack TM, Howell KG, Poduslo JF. Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies. Biochemistry. 2009 Nov 03; 48(43):10405-15.
    View in: PubMed
    Score: 0.052
  21. Ramakrishnan M, Wengenack TM, Kandimalla KK, Curran GL, Gilles EJ, Ramirez-Alvarado M, Lin J, Garwood M, Jack CR, Poduslo JF. Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging. Pharm Res. 2008 Aug; 25(8):1861-72.
    View in: PubMed
    Score: 0.047
  22. Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-Alvarado M, Kandimalla KK, Gilles EJ, Curran GL, Wengenack TM. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem. 2007 Jul; 102(2):420-33.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support